For the year ending 2025-12-31, OPK had -$62,873K decrease in cash & cash equivalents over the period. -$190,820K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | -225,680 |
| Depreciation and amortization | 91,627 |
| Non-cash interest | 66,257 |
| Amortization of deferred financing costs | 5,234 |
| Losses from investments in investees | -29 |
| Equity-based compensation employees and non-employees | 10,714 |
| Impairment charges | 1,007 |
| Realized loss (gain) on disposal of fixed assets and sales of equity securities | 3,245 |
| Change in fair value of equity securities and derivative instruments | -623 |
| Loss on conversion convertible senior notes | 0 |
| Inducement expense and loss on debt conversion | 32,647 |
| Change in fair value of contingent consideration | 0 |
| Deferred income tax provision | -14,999 |
| Gain on sale of assets | 101,576 |
| Accounts receivable, net | -30,213 |
| Inventory, net | 4,118 |
| Other current assets and prepaid expenses | 5,420 |
| Other assets | -23 |
| Accounts payable | -14,217 |
| Foreign currency measurement | 178 |
| Accrued expenses and other liabilities | -47,839 |
| Net cash used in operating activities | -178,542 |
| Investments in investees | 7,665 |
| Proceeds from sale of investments | 52,182 |
| Proceeds from the sale of property, plant and equipment | 287 |
| Capital expenditures | 12,278 |
| Proceeds from labcorp sale | 197,770 |
| Net cash provided by (used in) investing activities | 230,296 |
| Issuance of 3.00 convertible senior notes, net (including related parties) | 0 |
| Issuance of 2044 notes | 0 |
| Debt issuance costs | 0 |
| Share repurchase | 47,040 |
| Net activity from the exercise of common stock options and warrants | -256 |
| Repurchase of 2029 convertible notes | 62,208 |
| Borrowings on lines of credit | 33,033 |
| Repayments of lines of credit | 41,411 |
| Settlement of convertible notes | 174 |
| Net cash (used in) provided by financing activities | -118,056 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 3,429 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -62,873 |
| Cash, cash equivalents and restricted cash at beginning of period | 445,615 |
| Cash, cash equivalents and restricted cash at end of period | 382,742 |
OPKO HEALTH, INC. (OPK)
OPKO HEALTH, INC. (OPK)